Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05857566 · ClinicalTrials.gov registry record · Phase 1
Effect of RDX-002 on Postprandial Triglycerides in Subjects Treated With Olanzapine
A Phase 1 study, sponsored by Response Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT05857566 is a Phase 1 study that has completed, run by Response Pharmaceuticals. The registered enrollment target is 24 participants.
The verdict
NCT05857566, a Phase 1 study, has completed, sponsored by Response Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This Phase 1b Study RDX-002-22-09 has been planned to evaluate the effect of RDX-002 on postprandial triglycerides and ApoB48 levels in normal healthy subjects treated with the atypical antipsychotic drug, olanzapine.
Interventions
- DRUG RDX-002
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2023-05-16 |
| Est. Completion | 2023-09-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05857566
The ClinicalTrials.gov registry entry for NCT05857566 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Response Pharmaceuticals, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RDX-002 is the first listed.
NCT05857566 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05857566 about?
NCT05857566 is a clinical study titled "Effect of RDX-002 on Postprandial Triglycerides in Subjects Treated With Olanzapine". This Phase 1b Study RDX-002-22-09 has been planned to evaluate the effect of RDX-002 on postprandial triglycerides and ApoB48 levels in normal healthy subjects treated with the atypical antipsychotic drug, olanzapine.
What is the current status of trial NCT05857566?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2023-05-16. Estimated completion is 2023-09-13.
What interventions are being tested in trial NCT05857566?
The interventions under investigation include: RDX-002 (DRUG).
Who is sponsoring clinical trial NCT05857566?
This trial is sponsored by Response Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.